oxytetracycline--anhydrous and Pleuropneumonia--Contagious

Therapeutic management of contagious caprine pleuroneumonia (CCPP) involves mostly the use of oxytetracycline followed by enrofloxacin and rarely tylosin. In many parts of the world including India, the former antibiotics are commonly available than the latter. Therefore, prolonged use of the same leads to the development of antibiotic resistance and decreased efficacy of drug. Besides, inflammatory and allergic pathogenesis of CCPP envisages combination therapy. In this study, we evaluated the effectiveness of the combination therapy using different antibiotics (oxytetracycyline @ 10: group I, enrofloxacin @ 5 group II, and tylosin: group III, @ 10 mg/kg body weight), along with anti-inflammatory (meloxicam @ 0.5 mg/kg) and anti-allergic (pheneramine maleate @ 1.0 mg/kg) drugs. These drugs were given intramuscularly at the interval of 48 h for four times in three test groups (n = 10) of Pashmina goats, viz. groups I, II, and III, respectively, affected with CCPP. Group IV (n = 10) was kept as healthy control when group V (n = 10) treated with oxytetracycline @ 10 mg/kg alone was used as positive control. Clinical signs, clinical parameters, pro-inflammatory cytokine (tumor necrosis factor alpha (TNF-α)), and oxidative stress indices (total oxidant status (TOS), total antioxidant status (TAS)) were evaluated at hours 0, 48, 96, and 144 of experimental trial. Tylosin-based combination therapy resulted in a rapid and favorable recovery resulting in restoration of normal body temperature (102.46 ± 0.31 °F), respiration rate (16.30 ± 0.79 per minute), and heart rate (89.50 ± 2.63 per minute) compared to the oxytetracycline (102.95 ± 0.13, 21.30 ± 1.12, 86.00 ± 2.33, respectively) and enrofloxacin (102.97 ± 0.19, 21.00 ± 1.25, 90.00 ± 2.58, respectively) treated groups. By hour 144, all the groups showed restoration of clinical parameters of normal health and diminishing signs of CCPP, viz. fever, dyspnea, coughing, nasal discharge, weakness, and pleurodynia. Significant (P ≤ 0.05) decrease in levels of TNF-α and non-significant (P > 0.05) decrease in levels of TOS and an increase in levels of TAS were noted from hour 0 to 144 in all the test groups. Within the groups, no significant (P > 0.05) change was noted in TNF-α, TOS, and TAS levels; however, TNF-α levels were comparatively lower in group III. Hematological parameters did not differ significantly (P > 0.05). From these findings, it can be inferred that tylosin-based combination therapy is relatively be

Topics: Animals; Anti-Allergic Agents; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Drug Therapy, Combination; Enrofloxacin; Female; Goat Diseases; Goats; India; Meloxicam; Oxytetracycline; Pheniramine; Pleuropneumonia; Pleuropneumonia, Contagious; Pneumonia, Mycoplasma; Tylosin

Contagious bovine pleuropneumonia (CBPP) caused by Mycoplasma mycoides subspecies mycoides (Mmm) is an important disease of cattle that causes serious economic losses. With the known effectiveness of new generation macrolides, tulathromycin and gamithromycin were assessed in comparison with oxytetracycline as a positive control and saline as a negative control for effectiveness in inhibiting lung lesion development, promoting resolution, preventing spread and bacteriological clearance in susceptible local cattle breeds in two separate studies in Kenya and Zambia. Animals were monitored for clinical signs, sero-conversion as well as detailed post-mortem examination for CBPP lesions.. Using the Hudson and Turner score for lesion type and size, tulathromycin protected 90%, gamithromycin 80%, and oxytetracycline 88% of treated animals in Kenya. In Zambia, all animals (100%) treated with macrolides were free of lung lesions, while oxytetracycline protected 77.5%. Using the mean adapted Hudson and Turner score, which includes clinical signs, post-mortem findings and serology, tulathromycin protected 82%, gamithromycin 56% and oxytetracycline 80% of the animals in Kenya whereas in Zambia, tulathromycin protected 98%, gamithromycin 94% and oxytetracycline 80%. The saline-treated groups had 93 and 92% lesions in Kenya and Zambia respectively, with Mmm recovered from 5/14 in Kenya and 10/13 animals in Zambia. Whereas the groups treated with macrolides were free from lesions in Zambia, in Kenya 5/15 tulathromycin-treated animals and 6/15 gamithromycin-treated animals showed lesions. Oxytetracycline-treated animals showed similarities with 3/14 and 4/15 showing lesions in Zambia and Kenya respectively and Mmm recovery from one animal in Kenya and six in Zambia. In both studies, lesion scores of saline-treated groups were significantly higher than those of the antibiotic treated groups (p < 0.001). In sentinel animals, CBPP lesions were detected and Mmm recovered from one and two animals mixed with the saline-treated groups in Kenya and Zambia respectively.. This study demonstrated that tulathromycin, a mycoplasmacidal, can achieve metaphylactic protection of up to 80%, while non-recovery of Mmm from sentinels suggests macrolides effectiveness in preventing spread of Mmm. It is recommended that further studies are conducted to evaluate strategies comparing vaccination alone or combining vaccination and antibiotics to control or eradicate CBPP.

Topics: Animals; Anti-Bacterial Agents; Cattle; Cattle Diseases; Disaccharides; Heterocyclic Compounds; Kenya; Lung; Macrolides; Male; Mycoplasma mycoides; Oxytetracycline; Pleuropneumonia, Contagious; Zambia

Contagious bovine pleuropneumonia (CBPP) was recognised on Bako Agricultural Research Farm, in the Oromia Region of Ethiopia, for the first time on 5 May 2011. The outbreak was investigated by combining recognition of clinical signs, post-mortem examination, mycoplasma isolation and serological testing using competitive enzymelinked immunosorbent assay (c-ELISA). The clinical cases were monitored for eight months; sick animals were treated with a range of antibiotics and isolated if necessary. The outbreak of CBPP was confirmed both bacteriologically and serologically and had spread to almost the entire herd (96.7%) within the eight-month observation period. Of the animals that recovered after antibiotic treatment, 12.3% fell sick again, showed typical signs of CBPP and were considered to be carriers. The role of treatment in the prevention of the spread of CBPP was minimal. Newly purchased animals that were not tested and quarantined before being introduced onto the farm were suspected to have been the most probable source of infection.. La péripneumonie contagieuse bovine (PPCB) a été détectée pour la première fois dans la Ferme de recherches agricoles de Bako, dans l’Oromia (Éthiopie) le 5 mai 2011. Des investigations ont été conduites sur le foyer, au cours desquelles ont été réalisés des examens cliniques, des autopsies, des tentatives d’isolement de mycoplasmes et des tests sérologiques recourant à l’épreuve immuno-enzymatique de compétition (c-ELISA). Les cas cliniques ont été suivis pendant huit mois. Les animaux atteints ont été traités par antibiothérapie et mis à l’isolement si nécessaire. Le diagnostic de PPCB a été confirmé par les résultats tant bactériologiques que sérologiques ; le foyer s’est propagé dans tout le troupeau (96,7 %) au cours des huit mois de la période d’observation. Parmi les animaux ayant réagi au traitement antibiotique, 12,3 % ont eu une rechute accompagnée de signes cliniques caractéristiques de PPCB et ont donc été considérés comme porteurs. Le traitement n’a pas permis de prévenir significativement la propagation de la PPCB. Des animaux achetés et introduits dans la ferme peu de temps avant l’apparition du premier cas, sans avoir été préalablement testés ni soumis à une quarantaine, constituent la source la plus probable de l’infection.. El 5 de mayo de 2001 se detectó por primera vez perineumonía contagiosa bovina en la Granja de Investigación Agrícola de Bako, sita en la región etíope de Oromia. Para estudiar el brote se combinó la observación de signos clínicos con la realización de necropsias, el aislamiento de micoplasmas y pruebas serológicas con un ensayo inmunoenzimático de competición (ELISAc). Durante ocho meses se hizo un seguimiento de los casos clínicos, y los animales enfermos fueron tratados con diversos antibióticos y aislados en caso necesario. Tanto bacteriológica como serológicamente se confirmó la presencia de un brote de perineumonía contagiosa bovina, que en el curso de los ocho meses de observación se había propagado a la casi totalidad del rebaño (96,7%). De los animales que se recobraron tras recibir terapia antibiótica, un 12,3% recayeron con signos típicos de la enfermedad y fueron considerados portadores. El tratamiento tuvo un efecto mínimo para prevenir la diseminación del brote. Según se piensa, lo más probable es que la infección tuviera su origen en un conjunto de animales recién adquiridos que a su llegada a la granja no fueron sometidos ni a pruebas de detección ni a cuarentena.

Topics: Animals; Anti-Bacterial Agents; Antibodies, Bacterial; Cattle; Cattle Diseases; Disease Outbreaks; Ethiopia; Female; Lung; Male; Mycoplasma; Mycoplasma mycoides; Oxytetracycline; Penicillins; Pleuropneumonia, Contagious; Streptomycin; Tylosin

Mycoplasma mycoides subspecies mycoides Small Colony (MmmSC) is the causative agent of Contagious Bovine Pleuropneumonia (CBPP), a disease of substantial economic importance in sub-Saharan Africa. Failure of vaccination to curtail spread of this disease has led to calls for evaluation of the role of antimicrobials in CBPP control. Three major classes of antimicrobial are effective against mycoplasmas, namely tetracyclines, fluoroquinolones and macrolides. Therefore, the objectives of this study were to determine the effector kinetics of oxytetracycline, danofloxacin and tulathromycin against two MmmSC field strains in artificial medium and adult bovine serum.. Minimum inhibitory concentrations (MIC) were determined for oxytetracycline, danofloxacin and tulathromycin against MmmSC strains B237 and Tan8 using a macrodilution technique, and time-kill curves were constructed for various multiples of the MIC over a 24 hour period in artificial medium and serum. Data were fitted to sigmoid E(max) models to obtain 24 hour-area under curve/MIC ratios for mycoplasmastasis and, where appropriate, for mycoplasmacidal activity and virtual mycoplasmal elimination.. Minimum inhibitory concentrations against B237 were 20-fold higher, 2-fold higher and approximately 330-fold lower in serum than in artificial medium for oxytetracycline, danofloxacin and tulathromycin, respectively. Such differences were mirrored in experiments using Tan8. Oxytetracycline was mycoplasmastatic against both strains in both matrices. Danofloxacin elicited mycoplasmacidal activity against B237 and virtual elimination of Tan8; similar maximum antimycoplasmal effects were observed in artificial medium and serum. Tulathromycin effected virtual elimination of B237 but was mycoplasmastatic against Tan8 in artificial medium. However, this drug was mycoplasmastatic against both strains in the more physiologically relevant matrix of serum.. Oxytetracycline, danofloxacin and tulathromycin are all suitable candidates for further investigation as potential treatments for CBPP. This study also highlights the importance of testing drug activity in biological matrices as well as artificial media.

Topics: Animals; Anti-Infective Agents; Cattle; Colony Count, Microbial; Disaccharides; Fluoroquinolones; Heterocyclic Compounds; Microbial Sensitivity Tests; Models, Biological; Mycoplasma mycoides; Oxytetracycline; Pleuropneumonia, Contagious; Time Factors

Topics: Animals; Anti-Bacterial Agents; Dairying; Female; Goat Diseases; Goats; Greece; Mycoplasma capricolum; Oxytetracycline; Pleuropneumonia, Contagious; Treatment Outcome; Tylosin

In vitro minimum inhibitory concentrations were determined for 21 antimicrobials against 41 isolates of Mycoplasma mycoides subsp. mycoides small-colony type, the cause of contagious bovine pleuropneumonia. Of the antimicrobials used most widely in Africa, oxytetracycline and tilmicosin were effective, while the isolates were resistant to tylosin. These results provide a baseline for monitoring antimicrobial resistance.

Topics: Animals; Anti-Bacterial Agents; Cattle; Cattle Diseases; Drug Resistance, Bacterial; Macrolides; Microbial Sensitivity Tests; Mycoplasma mycoides; Oxytetracycline; Pleuropneumonia, Contagious; Tylosin

Minimum inhibitory concentrations (MIC) and minimum mycoplasmacidal concentrations (MMC) of the antimicrobials danofloxacin, florfenicol, oxytetracycline, spectinomycin and tilmicosin were determined in vitro for 20 isolates of Mycoplasma mycoides subspecies mycoides small colony type (MmmSC), the causative agent of contagious bovine pleuropneumonia (CBPP). The majority of strains were most susceptible to tilmicosin, followed by danofloxacin, oxytetracycline, florfenicol and spectinomycin with MIC50 values of 0.015, 0.25, 0.5, 1 and 8 microg/ml, and MMC50 values of 0.06, 0.5, 8, 8 and 16 microg/ml, respectively. However, tilmicosin had poor mycoplasmacidal activity against two recent strains from Portugal. There was no evidence of resistance to danofloxacin in any of the strains.

Topics: Animals; Anti-Bacterial Agents; Cattle; Cattle Diseases; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Fluoroquinolones; Macrolides; Mycoplasma mycoides; Oxytetracycline; Pleuropneumonia, Contagious; Spectinomycin; Thiamphenicol; Tylosin